Pfizer, through its wholly owned subsidiary Eclipse Acquisition, has completed the acquisition of biopharmaceutical company Icagen.
As per the agreement, each issued and outstanding share of Icagen common stock has been converted into the right to receive $6 in cash, without interest and less any applicable withholding and transfer taxes.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Icagen is now part of Pfizer’s worldwide R&D organisation, and will be integrated into Neusentis, Pfizer’s research unit.
